Press Room

ISySyCat21

Start
Tuesday, August 31, 2021 - 09:00
End
Friday, September 03, 2021 - 09:00
Location: Evora, Portugal
ISySyCat21 - Hovione gold sponsor catalysis

Hovione is present at the International Symposium on Synthesis and Catalysis 2021 (ISySyCat2021) taking place at the University of Evora in the historically recognized mediaeval city of Evora from August 31st to September 3rd 2021.

The conference will be a mixed event, in person to be hold in Evora, Portugal (with a limited number of participants) and on-line (webinar). 

The conference will focus on key topics in contemporary organic, organometallic, polymer synthesis and catalysis, which are of relevance to both academic and industrial chemists alike. This is reflected in the topics that will be discussed in the plenary lectures.

 

 

Hovione will present a topic at the plenary lectures with the following details:

 

Natural potential: biocatalyzed asymmetric synthesis of chiral amines

The presentation will address the screening and optimization of biocatalysts for the synthesis of chiral amines of interest in the manufacture of APIs.

Presenter: Ágnes Lakó
Date: 31st August
Time: 3:15 pm - 3:30 pm

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026